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Abstract
Thymic large cell neuroendocrine carcinomas (LCNECs) are very rare. We here describe a case in which the tumor
could be completely resected. A 55-year-old male was admitted to our hospital for treatment of an anterior
mediastinal tumor found at a regular health check-up. The patient underwent an extended thymectomy of an
invasive thymoma of Masaoka’s stage II that had been suspected preoperatively. The tumor was located in the
right lobe of the thymus and was completely resected. Final pathological diagnosis of the surgical specimen was
thymic LCNEC. The patient underwent adjuvant chemotherapy with irinotecan and cisplatin in accordance with the
diagnosis of a lung LCNEC, and is alive without recurrence or metastasis 16 months after surgery.
Background
Primary thymic neuroendocrine carcinomas (NECs)
were categorized under the rubric of ‘thymomas’ until
1972, when Rosai and Higa suggested that these tumors
were sufficiently distinctive to warrant classification as
carcinoid tumors [1]. Thymic NECs are relatively rare
neoplasms that account for only approximately 2% to
4% of all anterior mediastinal neoplasms [2]. In 1999,
the World Health Organization established thymic
epithelial tumor criteria and reclassified thymic carci-
noma, referring to NECs as a subtype [3]. In particular,
the LCNEC was subclassified in the thymic NECs in
accordance with the classification of pulmonary neu-
roendocrine tumors. Detailed clinical features of thymic
LCNECs are still unknown, however, because of their
rareness. We described a case with a review of the lit-
erature, focusing on the most likely optimal treatment it.
Case presentation
A 55-year-old Japanese male was admitted to the Kita-
sato University Hospital for further examination and
treatment for an abnormal shadow on the chest x-ray
found at a regular health check-up. He had smoked 35
packs per year for 20 years. Chest x-ray films showed a
solid mass with a clear border at the right hilum and a
negative silhouette sign for the right first arch (Figure
1). Enhanced chest computed tomography (CT) revealed
a solid mass 42 mm in diameter with a partially unclear
margin with the normal thymic tissue in the anterior
mediastinum (Figure 2). Magnetic resonance imaging
(MRI) using intravenous contrast medium showed isoin-
tensity of the mass on both T1- and T2-weighted
images (Figure 3, 4). Although chest CT and MRI
revealed no invasion of the superior vena cava and the
innominate vein, the tumor was highly suspected to
have invaded the normal thymic tissue. Laboratory find-
ings and results for tumor markers such as CEA (carci-
noembryonic antigen), NSE (neuron specific enolase),
and ProGRP (pro-gastrin releasing peptide) were all
within normal ranges, preoperatively.
Under the diagnosis of invasive thymoma or thymic
carcinoid, the patient under w e n ta ne x t e n d e dt h y m e c t -
omy. The tumor was intraoperatively revealed in the
right lobe of the thymus without any invasion to the
adjacent organs:the aorta, superior vena cava, pericar-
dium, bilateral phrenic nerve, or the right lung. Because
the tumor had invaded the right parietal pleura, we also
resected the right parietal pleura with a sufficient surgi-
cal margin.
Macroscopically, the elastic soft tumor surrounded by
thymic fat tissue was 40 × 35 × 28 mm in size. The cut
surface was mainly whitish-yellow in color and showed
focal necrosis and red bloody spots.
Microscopically, the tumor manifested morphologic
features of a carcinoid. The tumor cells were arranged
in wide trabeculae with irregular nests separated by thin
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any medium, provided the original work is properly cited.fibrovascular stroma, and scattered abortive rosette-like
structures (Figure 5). The tumor cells were oval to poly-
gonal in shape with abundant eosinophilic and granular
cytoplasm. The nuclear chromatin was granular and the
nucleoli were inconspicuous. Small foci of coagulative
necrosis were also observed (Figure 6). The average
mitotic count was 30 per each of 10 high-power fields
(Figure 7), and the Ki-67 indices using MIB-1 immuno-
histochemical staining ranged from 20% to 30%. Immu-
nohistochemically, the tumor cells were diffusely
positive for chromogranin A (Figure 8), synaptophysin,
and neural cell adhesion molecule (NCAM), confirming
a neuroendocrine nature. Thus, the final pathological
diagnosis of thymic LCNEC was made. The tumor also
invaded atrophic normal thymic tissue.
The patient underwent adjuvant chemotherapy based
on a platinum doublet containing cisplatin at 60 mg/m
2
and irinotecan at 60 mg/m
2 for three courses, and is
alive without recurrence or metastasis at 16 months
after surgery.
Discussion
The neuroendocrine subtype of thymus tumors is defined
on the basis of histopathological features and immunophe-
notypes. In recent studies [4,5], NECs have been morpho-
logically categorized into four main types: typical carcinoid,
atypical carcinoid, LCNEC, and small-cell carcinoma. To
our knowledge, LCNECs and small-cell carcinomas are
highly malignant and have a poorer prognosis than do
other thymic epithelial tumors. The LCNEC is included as
a separate entity because of differences from carcinoids in
survival rates as well as its incidence and clinical, epidemio-
logic, histological, and molecular characteristics.
Although chest CT and MRI revealed no invasion to
the superior vena cava or the innominate vein in the
Figure 1 Chest x-ray showing a solid mass with a clear border
at the right hilum and a negative silhouette sign for the right
first arch.
Figure 2 Enhanced chest CT scan revealing a 42-mm-sized
solid mass with an unclear margin (arrows) with the normal
thymus in the anterior mediastinum.
Figure 3 Chest MRI using intravenous contrast medium
showed iso-intensity of the mass on a T1-weighted image.
Figure 4 Chest MRI using intravenous contrast medium
showed iso-intensity of the mass on a T2-weighted image with
an unclear rim (arrows), as with the chest CT, too.
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strated isointensity, the tumor was highly suspected of
having invaded the normal thymic tissue due to its
unclear rim. Therefore, our preoperative diagnosis was
an invasive thymoma or a carcinoid.
For optimal treatment, an accurate pretherapeutic diag-
nosis is important. However, as a thymic tumor is not
always morphologically homogeneous, this may be diffi-
cult with a standard needle biopsy. Surgery offers the
best chance for a definitive diagnosis and curative treat-
ment of thymic tumors. The differential diagnosis for the
anterior mediastinum includes other primary mediastinal
tumors, mainly thymoma, paraganglioma, lymphoma,
parathyroid adenoma or carcinoma, as well as medullary
carcinoma of the thyroid. The most difficult but most
important differential diagnosis in this setting is with
thymoma, particularly of the spindle cell type. This latter
can often show areas displaying a prominent neuroendo-
crine appearance with abundant epithelial cells disposed
radially around an empty space closely simulating the
microacinar growth pattern sometimes observed in carci-
noids. To make a successful differential diagnosis, immu-
nohistochemical staining can be helpful. Even though
both types of lesions share strong CAM 5.2 positivity,
thymomas are negative for neuroendocrine markers (e.g.
chromogranin A, synaptophysin, NCAM, and CD56) and
may be useful for NECs [6].
Thymic LCNEC is very rare. A search of the PubMed
database revealed only a few case reports in the litera-
ture [7-11]. Mega et al. reviewed 10 cases of thymic
LCNECs in Japan [7]. As seen in Table 1, surgical resec-
tion was performed in 8 of the 10 cases, but most of the
patients were at an advanced stage of disease and half
Figure 5 The tumor cells were arranged in wide trabeculae
with irregular nests separated by thin fibrovascular stroma,
and scattered abortive rosette-like structures were
encountered. (hematoxylin and eosin staining, ×40).
Figure 6 Small foci of coagulative necrosis were also observed.
(hematoxylin and eosin staining, ×100).
Figure 7 Mitosis(arrows) counts ranged around 30 per 10 high-
power fields. (hematoxylin and eosin staining, ×400).
Figure 8 Tumor cells were diffusely positive for chromogranin
A (×400).
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tively soon after surgery (range 2 to 7 months) and their
prognoses were very poor. Cesar et al. reported [6], the
primary mediastinal NEC to represent a separate biolo-
g i ce n t i t yf r o mc a r c i n o i d sa rising at other locations,
with disease-free survivals of 50% at 5 years and 9% at
10 years for well differentiated tumors (i.e. typical carci-
noids), 20% at 5 years and 0% at 10 years for moderately
differentiated tumors (i.e. atypical carcinoids), and 0% at
5 years for poorly differentiated tumors. Therefore, it
can be considered that a well differentiated grade and
complete surgical removal followed by adjuvant therapy
offer curative potential and are significant factors for
prolonged survival [7-9].
Currently, there is no evidence to support the use of
postoperative therapy for Thymic LCNECs. Recent stu-
dies [12-14] of LCNEC of the lung recommended post-
operative administration of adjuvant chemotherapy with
platinum-based combination regimens (e.g. etoposide
and others), which is the regimen for small cell lung
carcinoma similar to the clinicopathologic and biologic
features of LCNEC. Their results showed good prog-
nosis. Platinum-based combination regimens were effec-
tive for the patients with LCNEC in their studies.
Likewise, we believe that surgery and adjuvant therapy
are needed to treat LCNEC in the thymus. Therefore we
selected the regimen, cisplatin/irinotecan, for small cell
lung carcinoma because Noda et al. revealed that cispla-
tin/irinotecan provided better results than did cisplatin/
etoposide [15]. And Fujiwara et al. [16] also indicated
that irinotecan-based regimens might be as active
against LCNEC of the lung as against SCLC. Since
recurrence of thymic LCNECs occurs within a short
duration after surgery and their prognosis is very poor,
we regarded this disease as having an extensive status at
resection. Therefore, we selected the regimen, cisplatin/
irinotecan. However, the odalities for adjuvant che-
motherapy remain to be defined.
Conclusion
Because primary thymic LCNECs are very rare, and the
patients’prognoses are very poor, along with the lack of
experience, a standardized treatment protocol, and the
limited literature, all these contributing factors make it a
difficult tumor to treat. Additional studies area war-
ranted to determine the optimal treatment of thymic
LCNECs.
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